中东和非洲制药业务洞察

Thirty-Eighth Edition Report Release Date: February 2026Analytical Timeframe: MAT Sep 2025 © 2026. All rights reserved. IQVIA®is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.© 2026. All rights reserved. IQVIA®is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. Disclaimer IQVIA is not an “authorised person” for the purposes of the Financial Services and Markets Act 2000 (“FSMA”) anddoes not provide investment advice or carry on any other regulated activity under Part II of the FSMA 2000(Regulated Activities) Order 2001 The forecasts, projections, and related information contained herein are made and provided subject to theassumptions, methodologies, caveats, and variables described in this report and are based on third party sourcesand data reasonably believed to be reliable. No warranty is made as to the completeness or accuracy of suchthird party sources or data This report, in part or in whole, is not intended to constitute investment advice, and is not a recommendation topurchase or not purchase, an endorsement of, or an opinion as to the value of, any security or any investmentinstrument of any entity As with any attempt to estimate future events, the forecasts, projections, conclusions, and other informationincluded herein are subject to certain risks and uncertainties, and are not to be considered guarantees of anyparticular outcome This report shall not be published, nor shall any public references to IQVIA be made regarding these services or thisreport, without IQVIA’ prior written approval. When so provided, this report and the information herein must alwaysbe provided and used in its entirety, including this complete Disclaimer page This report is subject to the IQVIA General Terms and Conditions Agenda •Newsletter report summary•Regional summary and analysis•Spotlight on new offering•Appendix Business insights snapshot MAT Q3 2025:Many countries have witnessed high growth in 2025 Among the key countries, KSA saw growth of 20.7% and continues tolead, accounting for 36.9% of sales in MEA Region South Africa1 United Arab Emirates (UAE) •South Africa has grown by 1.41% PPG accounting for$3.6 B saleswith theretail channel accounting for 84.6%of total sales•Cough & Cold Preparations TA continues to be Top TA at-3.6% PPG and 6.1% share•Top 10 corporationsaccount for50.9%share in sales.Adcock Ingram, a local firm, is leading with9.8%shareandNovo Nordiskbeing the fastest growing at25.8%PPG •UAE grew by 11.89% PPG (3rdfastest growing country inMEA region**)accounting for $5.08 B sales•Top 10 TAsaccount for49.1%of total sales, whereinNewer Gen Type II Antidiabetics TA is growing at7.0% PPG•Top 10 corporationsaccount for47% sharein sales withPfizerbeing the fastest growing at20.7% PPG; mainlydriven by top brands like Prevnar (149.8%), Nurtec (14,1%),and Ixifi (45.7%) on PPG Saudi Arabia (KSA) Egypt (EGY)* •Saudi Arabia has grown by 20.66% PPG, making it thefastest growing country in MEA, with sales valued at$15.02 B•Hospital channel (Hospitals + LPO) grew by 26.94% PPGand accounting for50.8% of total sales•Top 10 corporationsaccount for43.2%share in sales.Hikma Pharmais leading with6. 8%shareand30.5%PPG•Hikma Pharmais the fastest growing Local/Reg corp mainlydriven by top brands likeRemsima (140.4%), Amoclan(13.9%), Omeral (32.1%) and Torvast (24.2%) on PPG •Egypt volume sales has increased by 6.98% PPGdrivenby growth fromRetail channel (5.85% PPG) accountingfor 81.1% of country’s Units sales•Systemic Antibacterialsis the top TA in Egypt with10.2%Units share whileDermatological Anti-Infectives (12.1%PPG) is the fastest growingamongst the top 10 TAs•Top 10 corporations account for 41.3% sharein volumesales,Pharco is leadingthe sales with7.8% share andAmoun Pharma isthe fastest growing corporation amongtop 10 corps(39.2% PPG) Algeria business in MEA is growing at 5.28% PPG mainly driven bylocal/regional players with 11.64% PPG Algeria (ALG) Fr. West Africa (FWA) FWA •FWA retail channel has grown by 8,03% PPG accountingfor $2.0 B sales inMAT Q3 2025•Local/Regional playersgrew by10.75% PPGwhileaccounting for52.55% of total sales•Amongst the top 10 corporations,Sanoficontinues to bethetopselling corporation with5.52% sharewhileGenericHealthcare is the fastest growing top corporation at30.1% PPGamongst the top 10 corporations.•Generic Healthcaregrowth is driven by top products likeAmloperin (31.0% PPG), Ramithiazide (14.4% PPG) andArtrim (10.6% PPG) •Algeria retail channel sales increased by 5.28% PPGaccounting for$2.8 Bsales in MAT Q3 2025•Top TAsareAntihypertensives(5.4% PPG) andInsulin &Analogs(3.1% PPG).Traditional Type II Antidiabetesisthe fastest growing at10.2% PPGamongst the top 10 TAs(excl. NonTherapeutics)•MS Pharma is the top corporationwith7.1% of salesshareandBiocare Biotech SPis fastest growing amongthetop 10corporations (69.6%) on PPG•Amongst the top pro